|
- 2019
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatmentDOI: 10.1002/acn3.700 Abstract: To compare 2‐year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS)
|